WHAT THIS STUDY ADDS
In our patients, determinations of serum levels of micafungin were performed and 100% of the levels exceeded the threshold of 0.25 mg/L, regardless of age, weight, administered dose, albumin levels, creatinine and the presence or absence of graft-versus-host disease (GVHD).
The poor interaction of micafungin with other drugs, its safety profile and the administration on alternating days suggest a decrease in toxicity and days of hospitalization, especially for patients with SCD, without an increase in breakthrough on alternating days in pediatric patients.